Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astra

Executive Summary

Files supplemental NDA for Foscavir (foscarnet) injection as a second-line treatment for herpes simplex virus, firm announces Nov. 19. The SNDA is for the treatment of both HSV-1 and HSV-2 resistant to acyclovir (Burroughs Wellcome's Zovirax). Foscavir may be obtained for patients with herpes who are unresponsive to standard therapy under a compassionate use program originally set up for Foscavir before its Sept. 27, 1991 approval for AIDS-related cytomegalovirus retinitis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel